Año 2022 / Volumen 114 / Número 12
Editorial
New actors come into play against hepatitis delta

702-704

DOI: 10.17235/reed.2022.9050/2022

Mar Riveiro-Barciela, Adriana Palom, Maria Buti,

Resumen
Currently chronic hepatitis delta (CHD) represents the most severe form of chronic viral hepatitis. The risk of developing cirrhosis, hepatocellular carcinoma (HCC) and decompensated liver disease is 2-3 times greater in hepatitis delta virus (HDV) infection than in hepatitis B virus (HBV). For instance, in a study carried out in Italy including 299 CHD patients followed for 28 years, 82 (27%) developed cirrhosis, and among these, 46 (56%) developed HCC. The real number of subjects infected by HDV worldwide remains unknown due to the lack of information in many areas, though it has been suggested that the rate of HBsAg carriers co-infected by HDV may be situated between 4.5 and 18%.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. Journal of hepatology. 2021;74(5):1200-1211.
2. Farci P, Niro GA. Clinical features of hepatitis D. Seminars in liver disease. 2012;32(3):228-236.
3. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629-1638.
4. Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2018.
5. Wedemever H, Yurdaydin C, Dalekos GN, et al. 72 week data of the HIDIT‑1 trial: A multicenter randomised study comparing peginterferon alpha‑2a plus adefovir vs. peginterferon alpha‑2a plus placebo vs. adefovir in chronic delta hepatitis. Journal of hepatology. 2007;46(Supplement 1):S4
6. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. The New England journal of medicine. 2011;364(4):322-331.
7. Palom A, Rodríguez-Tajes S, Navascués CA, et al. Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Alimentary pharmacology & therapeutics. 2020;51(1):158-166.
8. Palom A, Sopena S, Riveiro-Barciela M, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. Alimentary pharmacology & therapeutics. 2021;54(4):462-469.
9. Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. Journal of hepatology. 2016;65(3):490-498.
10. Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. Journal of hepatology. 2018;68(Supplement 1):S3
11. Wedemeyer H, Schöneweis K, Bogomolov P, et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in combination with PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. Journal of hepatology. 2019;70(Suppl 1):e81.
12. Wedemeyer H, Aleman S, Andreone P, et al. Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study. Journal of hepatology. 2021;75(Suppl 2):S294.
13. Wedemeyer H, Aleman S, Brunetto M, et al. Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study. Journal of hepatology. 2022;77(S1):S4.
14. Asselah T, Loureiro D, Le Gal F, et al. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life. Liver international : official journal of the International Association for the Study of the Liver. 2021;41(7):1509-1517.
15. Jachs M, Schwarz C, Panzer M, et al. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A "real world" Study. Alimentary pharmacology & therapeutics. 2022.
16. Loglio A, Ferenci P, Uceda Renteria SC, et al. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. Journal of hepatology. 2022;76(2):464-469.
17. Fontaine H, Fougerou-Leurent C, Gordien E, et al. Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort. Journal of hepatology. 2022;77(S1):S72.
18. Einav S, Glenn JS. Prenylation inhibitors: a novel class of antiviral agents. The Journal of antimicrobial chemotherapy. 2003;52(6):883-886.
19. Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. The Lancet Infectious diseases. 2015;15(10):1167-1174.
20. Yurdaydin C, Keskin O, Kalkan C, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. Hepatology (Baltimore, Md). 2018;67(4):1224-1236.
21. Yurdaydin C, Keskin O, Yurdcu E, et al. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology (Baltimore, Md). 2022;75(6):1551-1565.
22. Etzion O, Hamid S, Lurie Y, et al. End of Study Results from LIMT HDV Study: 36% Durable Virologic Response at 24 Weeks Post-Treatment with Pegylated Interferon Lambda Monotherapy in Patients with Chronic HDV Infection. Journal of hepatology. 2019;70(1):e32.
23. Bazinet M, Pantea V, Cebotarescu V, et al. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. The lancet Gastroenterology & hepatology. 2017;2(12):877-889.
Artículos relacionados

Editorial

Tratamiento de la trombosis venosa portal en el paciente con cirrosis

DOI: 10.17235/reed.2023.9800/2023

Carta

Reactivación del virus de la hepatitis B por ibrutinib

DOI: 10.17235/reed.2023.9587/2023

Carta

Hemoperitoneo por rotura de varices intraabdominales

DOI: 10.17235/reed.2022.8937/2022

Carta

Patrón cirrótico en la sarcoidosis hepática avanzada

DOI: 10.17235/reed.2021.8446/2021

Imagen en Patología Digestiva

Hepatocarcinoma quístico gigante en ausencia de cirrosis

DOI: 10.17235/reed.2021.8313/2021

Revisión

La fragilidad física en el contexto del trasplante hepático

DOI: 10.17235/reed.2020.7448/2020

Instrucciones para citar
Riveiro-Barciela M, Palom A, Buti M. New actors come into play against hepatitis delta. 9050/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 878 veces.
Este artículo ha sido descargado 108 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 01/07/2022

Aceptado: 31/07/2022

Prepublicado: 31/08/2022

Publicado: 12/12/2022

Tiempo de prepublicación: 61 días

Tiempo de edición del artículo: 164 días


Compartir
Este artículo ha sido valorado por 1 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas